ESMO2023: Phase I open-label, dose escalation and expansion study of YH003, an anti-CD40 agonist monoclonal antibody in combination with Toripalimab in patients (pts) with advanced solid tumours
YH003 was well tolerated up to 1.0 mg/kg dose levels when combined with Toripalimab. Based on the safety, efficacy and PK data of YH003002, the RP2D of YH003 for part 2 expansion stage was 0.3 mg/kg. The combination of YH003 and Toripalimab has shown encouraging antitumor activity in patients with advanced solid tumors.
+86-010-56967680
010-56967601
ir@bbctg.com.cn
Copyright © 2024 Biocytogen. All Rights Reserved
Powered by Fractal-technology